Sidtis J J, Dafni U, Slasor P, Hall C, Price R W, Kieburtz K, Tucker T, Clifford D B
Department of Neurology, University of Minnesota, Minneapolis, USA.
J Neurovirol. 1997 Jun;3(3):233-40. doi: 10.3109/13550289709018299.
AIDS Dementia Complex (ADC) is a frequent and devastating complication of HIV infection. There is evidence that zidovudine (ZDV) has an effect in alleviating the symptoms of ADC, and may have a role in its prevention. It is therefore important that new antiretroviral therapies be evaluated not only for the risk of neurologic side effects, but also for their relative efficacy to ZDV in the prevention of ADC. The present study reports the effects of 2'3'-dideoxyinosine (DDI, didanosine, Videx) therapy on neuropsychological performance in the context of several large clinical trials targeting advanced systemic HIV-1 infection. Subjects treated with DDI had stable neurologic performance in quantitative tests over a 1 year period and were similar to zidovudine treated subjects.
艾滋病痴呆综合征（ADC）是HIV感染常见且严重的并发症。有证据表明齐多夫定（ZDV）对缓解ADC症状有效，且可能在预防方面发挥作用。因此，评估新的抗逆转录病毒疗法不仅要考虑其神经副作用风险，还要考虑其在预防ADC方面相对于ZDV的相对疗效，这一点很重要。本研究报告了在针对晚期全身性HIV-1感染的几项大型临床试验背景下，2',3'-双脱氧肌苷（DDI，去羟肌苷，惠妥滋）治疗对神经心理表现的影响。接受DDI治疗的受试者在1年的定量测试中神经功能表现稳定，与接受齐多夫定治疗的受试者相似。
